|
1
|
Schratz KE and Armanios M: Cancer and
myeloid clonal evolution in the short telomere syndromes. Curr Opin
Genet Dev. 60:112–118. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cai SF and Levine RL: Genetic and
epigenetic determinants of AML pathogenesis. Semin Hematol.
56:84–89. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weinberg OK, Sohani AR, Bhargava P and
Nardi V: Diagnostic work-up of acute myeloid leukemia. Am J
Hematol. 92:317–321. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Long L, Assaraf YG, Lei ZN, Peng H, Yang
L, Chen ZS and Ren S: Genetic biomarkers of drug resistance: A
compass of prognosis and targeted therapy in acute myeloid
leukemia. Drug Resist Updat. 52:1007032020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang GX, Ma GL, Li H, Huang T, Xiong J and
Hu JF: Advanced natural products chemistry research in China
between 2015 and 2017. Chin J Nat Med. 16:881–906. 2018.PubMed/NCBI
|
|
6
|
Mansoori B, Mohammadi A, Amin Doustvandi
M, Mohammadnejad F, Kamari F, Gjerstorff MF, Baradaran B and
Hamblin MR: Photodynamic therapy for cancer: Role of natural
products. Photodiagnosis Photodyn Ther. 26:395–404. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gao C, Yu S and Liang Q: New research
progress on Rabdosia japonica var. glaucocalyx. J Mudanjiang Med
Univ. 32:54–56. 2011.(In Chinese).
|
|
8
|
Su Y, Cui J, Shi W, Wang X and Zhou Y:
Research progress on Chinese herbal medicine isodon. Asia Pac
Tradit Med. 7:155–161. 2011.(In Chinese).
|
|
9
|
Dong R, Gao H and Liu Z: Research progress
on the biological activities of diterpenoids from isodon
(lamiaceae). China Pharm. 21:651–653. 2010.(In Chinese).
|
|
10
|
Lin W, Xie J, Xu N, Huang L, Xu A, Li H,
Li C, Gao Y, Watanabe M, Liu C and Huang P: Glaucocalyxin A induces
G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway
in human bladder cancer cells. Int J Biol Sci. 14:418–426. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hou X, Xu G, Wang Z, Zhan X, Li H, Li R,
Shi W, Wang C, Chen Y, Ai Y, et al: Glaucocalyxin A alleviates
LPS-mediated septic shock and inflammation via inhibiting NLRP3
inflammasome activation. Int Immunopharmacol. 81:1062712020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gan P, Zhang L, Chen Y, Zhang Y, Zhang F,
Zhou X, Zhang X, Gao B, Zhen X, Zhang J and Zheng LT:
Anti-inflammatory effects of glaucocalyxin B in microglia cells. J
Pharmacol Sci. 128:35–46. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pan Y, Bai J, Shen F, Sun L, He Q and Su
B: Glaucocalyxin B induces apoptosis and autophagy in human
cervical cancer cells. Mol Med Rep. 14:1751–1755. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wei MQ, Chen L, Zhang WQ, Sun M, Wang JJ,
Zhan JP, Wang CL and Yan C: Chemical constituents from Isodon
suzhouensis and their anti-tumor activity. Nat Prod Res Deve.
37:262–270+261. 2024.(In Chinese).
|
|
15
|
Zhao L, Zhang H, Li N, Chen J, Xu H, Wang
Y and Liang Q: Network pharmacology, a promising approach to reveal
the pharmacology mechanism of Chinese medicine formula. J
Ethnopharmacol. 309:1163062023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yuan Z, Pan Y, Leng T, Chu Y, Zhang H, Ma
J and Ma X: Progress and prospects of research ideas and methods in
the network pharmacology of traditional Chinese medicine. J Pharm
Pharm Sci. 25:218–226. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dean PN and Jett JH: Mathematical analysis
of DNA distributions derived from flow microfluorometry. J Cell
Biol. 60:523–527. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu XJ, Li YM, Gu JY, Guo M and Fei J:
Enhanced Chemosensitivty of Leukemic Cells to Cytarabine by
Targeted Suppression of miRNA-21. Life Sci Res. 15:317–322.
2011.(In Chinese).
|
|
19
|
Wang ES, Montesinos P, Foran J, Erba H,
Rodríguez-Arbolí E, Fedorov K, Heiblig M, Heidel FH, Altman JK,
Baer MR, et al: Ziftomenib in relapsed or refractory NPM1-mutated
AML. J Clin Oncol. 43:3381–3390. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Atanasov AG, Waltenberger B,
Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, Temml V, Wang L,
Schwaiger S, Heiss EH, et al: Discovery and resupply of
pharmacologically active plant-derived natural products: A review.
Biotechnol Adv. 33:1582–1614. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aung TN, Qu Z, Kortschak RD and Adelson
DL: Understanding the effectiveness of natural compound mixtures in
cancer through their molecular mode of action. Int J Mol Sci.
18:6562017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hirose R, Miura T, Sha R, Shinkai Y,
Tanaka-Kagawa T and Kumagai Y: A method for detecting covalent
modification of sensor proteins associated with
1,4-naphthoquinone-induced activation of electrophilic signal
transduction pathways. J Toxicol Sci. 37:891–898. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Furtek SL, Backos DS, Matheson CJ and
Reigan P: Strategies and approaches of targeting STAT3 for cancer
treatment. ACS Chem Biol. 11:308–318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fasouli ES and Katsantoni E: JAK-STAT in
early hematopoiesis and leukemia. Front Cell Dev Biol.
9:6693632021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
How J, Garcia JS and Mullally A: Biology
and therapeutic targeting of molecular mechanisms in MPNs. Blood.
141:1922–1933. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jaśkiewicz A, Domoradzki T and Pająk B:
Targeting the JAK2/STAT3 pathway-can we compare it to the two faces
of the god janus? Int J Mol Sci. 21:82612020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Agashe RP, Lippman SM and Kurzrock R: JAK:
Not just another kinase. Mol Cancer Ther. 21:1757–1764. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qin JJ, Yan L, Zhang J and Zhang WD: STAT3
as a potential therapeutic target in triple negative breast cancer:
A systematic review. J Exp Clin Cancer Res. 38:1952019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao SP, Mark KG, Leslie K, Pao W, Motoi N,
Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B and Bromberg
JF: Mutations in the EGFR kinase domain mediate STAT3 activation
via IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Banerjee S, Biehl A, Gadina M, Hasni S and
Schwartz DM: JAK-STAT signaling as a target for inflammatory and
autoimmune diseases: Current and future prospects. Drugs.
77:521–546. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Salas A, Hernandez-Rocha C, Duijvestein M,
Faubion W, McGovern D, Vermeire S, Vetrano S and Vande Casteele N:
JAK-STAT pathway targeting for the treatment of inflammatory bowel
disease. Nat Rev Gastroenterol Hepatol. 17:323–337. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hegde S, Ni S, He S, Yoon D, Feng GS,
Watowich SS, Paulson RF and Hankey PA: Stat3 promotes the
development of erythroleukemia by inducing Pu.1 expression and
inhibiting erythroid differentiation. Oncogene. 28:3349–3359. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen C, Lu M, Lin S and Qin W: The nuclear
gene rpl18 regulates erythroid maturation via JAK2-STAT3 signaling
in zebrafish model of Diamond-Blackfan anemia. Cell Death Dis.
11:1352020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fuchs Y: The therapeutic promise of
apoptosis. Science. 363:1050–1051. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Talib WH: Melatonin and cancer hallmarks.
Molecules. 23:5182018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nabih NW, Hassan HAFM, Preis E, Schaefer
J, Babker A, Abbas AM, Amin MU, Bakowsky U and Fahmy SA:
Antibody-functionalized lipid nanocarriers for RNA-based cancer
gene therapy: Advances and challenges in targeted delivery.
Nanoscale Adv. 7:5905–5931. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wafik Nabih N, Nafie MS, Babker A, Hassan
HAFM and Fahmy SA: Recent advances in nano vehicles encapsulating
cinnamic acid and its derivatives as promising anticancer agents.
RSC Adv. 15:20815–20847. 2025. View Article : Google Scholar : PubMed/NCBI
|
![Enrichment analysis. (A) GO
biological function analysis; (B) KEGG pathway enrichment analysis:
Top 20 significantly enriched pathways [-log10 (P-value)]. GO, Gene
Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.](/article_images/ol/31/6/ol-31-06-15622-g01.jpg)
